CN1246462C - 修饰的维生素k依赖性多肽 - Google Patents

修饰的维生素k依赖性多肽 Download PDF

Info

Publication number
CN1246462C
CN1246462C CNB988125811A CN98812581A CN1246462C CN 1246462 C CN1246462 C CN 1246462C CN B988125811 A CNB988125811 A CN B988125811A CN 98812581 A CN98812581 A CN 98812581A CN 1246462 C CN1246462 C CN 1246462C
Authority
CN
China
Prior art keywords
albumen
xaa
factor
active
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988125811A
Other languages
English (en)
Chinese (zh)
Other versions
CN1283231A (zh
Inventor
G·L·内尔塞施图恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota
Original Assignee
University of Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota filed Critical University of Minnesota
Publication of CN1283231A publication Critical patent/CN1283231A/zh
Application granted granted Critical
Publication of CN1246462C publication Critical patent/CN1246462C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CNB988125811A 1997-10-23 1998-10-20 修饰的维生素k依赖性多肽 Expired - Fee Related CN1246462C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/955,636 1997-10-23
US08/955,636 US6017882A (en) 1997-10-23 1997-10-23 Modified vitamin K-dependent polypeptides

Publications (2)

Publication Number Publication Date
CN1283231A CN1283231A (zh) 2001-02-07
CN1246462C true CN1246462C (zh) 2006-03-22

Family

ID=25497114

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988125811A Expired - Fee Related CN1246462C (zh) 1997-10-23 1998-10-20 修饰的维生素k依赖性多肽

Country Status (30)

Country Link
US (1) US6017882A (ko)
EP (2) EP1676919B1 (ko)
JP (1) JP4276379B2 (ko)
KR (1) KR20010031370A (ko)
CN (1) CN1246462C (ko)
AP (1) AP2000001811A0 (ko)
AR (2) AR020048A1 (ko)
AT (1) ATE390486T1 (ko)
AU (1) AU749279C (ko)
BR (1) BR9814611A (ko)
CA (1) CA2307175C (ko)
DE (1) DE69839313T2 (ko)
DK (1) DK1090128T3 (ko)
EA (1) EA200000449A1 (ko)
ES (2) ES2303362T3 (ko)
HR (1) HRP20000234A2 (ko)
HU (1) HU225993B1 (ko)
ID (1) ID26330A (ko)
IL (1) IL135603A0 (ko)
IS (1) IS5449A (ko)
MY (1) MY136336A (ko)
NO (1) NO20002025L (ko)
NZ (1) NZ504114A (ko)
PL (1) PL194194B1 (ko)
PT (1) PT1090128E (ko)
SG (1) SG105547A1 (ko)
TR (1) TR200001105T2 (ko)
TW (1) TW587081B (ko)
WO (1) WO1999020767A1 (ko)
ZA (1) ZA989597B (ko)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
JP2003514545A (ja) * 1999-11-19 2003-04-22 イーライ・リリー・アンド・カンパニー プロテインｃ誘導体
ES2234807T3 (es) 2000-02-02 2005-07-01 Eli Lilly And Company Derivados de proteina c.
EP1263943A1 (en) 2000-02-11 2002-12-11 Eli Lilly & Company Protein c derivatives
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) * 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
WO2002009678A2 (en) * 2000-07-31 2002-02-07 Ottawa Heart Institute Research Corporation Charged phospholipid compositions and methods for their use
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
JP2004527239A (ja) * 2001-03-02 2004-09-09 テイ・エイ・シー・スロムボシス・アンド・コアグラシヨン・エイ・ビー プロテインｃ変異体
US20050176083A1 (en) * 2002-03-01 2005-08-11 Bjorn Dahlback Recombinant protein c variants
US20030186862A1 (en) * 2002-04-02 2003-10-02 Nelsestuen Gary L. Factor VIIa compositions
AU2003221469A1 (en) * 2002-04-30 2003-11-17 Bayer Healthcare Llc FACTOR VII OR VIIa POLYPEPTIDE VARIANTS
US20030232075A1 (en) * 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
PL207018B1 (pl) 2002-06-21 2010-10-29 Novo Nordisk Helth Care Ag Kompozycja farmaceutyczna, sposób przygotowania stabilnego polipeptydu czynnika VII i zastosowanie polipeptydu czynnika VII
US20040176704A1 (en) * 2003-03-04 2004-09-09 Stevens Timothy A Collection device adapted to accept cartridge for point of care system
KR101204712B1 (ko) 2003-03-18 2012-11-27 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Ｇｌａ-잔기 함유 세린 프로테아제의 제조 방법
AU2004221761B2 (en) 2003-03-20 2010-01-07 Bayer Healthcare Llc FVII or FVIIa variants
NZ573412A (en) * 2003-06-19 2010-09-30 Maxygen Holdings Ltd Factor VII or VIIa Gla domain variants
JP4824559B2 (ja) 2003-09-09 2011-11-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 凝固因子ｖｉｉポリペプチド
KR100755967B1 (ko) * 2003-10-23 2007-09-06 한국타이어 주식회사 타이어의 비드와 휠의 갭 측정장치
EP3594222B1 (en) 2003-12-01 2022-08-03 Novo Nordisk Health Care AG Virus filtration of liquid factor vii compositions
CA2549593C (en) 2003-12-19 2014-02-11 Novo Nordisk Health Care Ag Stabilised compositions of factor vii polypeptides
ES2642214T3 (es) 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
KR101364001B1 (ko) 2004-12-23 2014-02-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 관심있는 비타민 ｋ-의존성 단백질을 포함한 조성물 중의단백질 오염물질의 양의 감소
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
EP1893230A2 (en) * 2005-04-26 2008-03-05 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
ES2397851T3 (es) 2005-07-13 2013-03-11 Novo Nordisk Health Care Ag Células de inactivación proteínica de la célula huésped para la producción de proteínas terapéuticas
ES2515915T3 (es) 2005-09-01 2014-10-30 Novo Nordisk Health Care Ag Purificación de los polipéptidos del Factor VII mediante cromatografía de interacción hidrofóbica
WO2007031559A2 (en) 2005-09-14 2007-03-22 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
JP5570809B2 (ja) 2006-09-01 2014-08-13 ノボ ノルディスク ヘルス ケア アーゲー 修飾タンパク質
WO2008078189A2 (en) * 2006-12-20 2008-07-03 Bayer Healthcare Llc Factor vii and viia compositions
NZ579985A (en) 2007-04-13 2012-02-24 Catalyst Biosciences Inc Modified factor vii polypetides and uses thereof
US20080305157A1 (en) * 2007-06-08 2008-12-11 University Of Maryland Office Of Technology Commercialization Encapsulation and separation of charged organic solutes inside catanionic vesicles
EP2574676B1 (en) 2007-12-27 2017-08-30 Baxalta GmbH Cell culture processes
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
TWI626057B (zh) 2009-06-09 2018-06-11 普龍製藥有限責任公司 血紅素組成物
EP2514760B1 (en) * 2009-12-14 2015-10-21 National University Corporation Hokkaido University Peptides imparting cell permeability to lipid membrane structure
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
US9145552B2 (en) 2012-07-25 2015-09-29 Catalyst Biosciences, Inc. Modified factor X polypeptides and uses thereof
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
EP3833381B1 (en) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2799316B2 (ja) * 1987-06-12 1998-09-17 ヘキスト・マリオン・ルセル株式会社 雑種ヒトプロテインｃおよびその遺伝子工学的製法
JPH0246296A (ja) * 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
DE69131292T2 (de) * 1990-01-29 1999-09-30 Zymogenetics, Inc. Antikoagulierende proteine
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII

Also Published As

Publication number Publication date
TR200001105T2 (tr) 2000-09-21
AU2702499A (en) 1999-05-10
HUP0102257A3 (en) 2003-09-29
ZA989597B (en) 1999-04-23
US6017882A (en) 2000-01-25
KR20010031370A (ko) 2001-04-16
DE69839313T2 (de) 2009-04-16
EP1676919B1 (en) 2014-07-23
ES2303362T3 (es) 2008-08-01
CN1283231A (zh) 2001-02-07
AU749279B2 (en) 2002-06-20
HRP20000234A2 (en) 2001-08-31
EP1090128A1 (en) 2001-04-11
TW587081B (en) 2004-05-11
ES2496104T3 (es) 2014-09-18
DE69839313D1 (de) 2008-05-08
WO1999020767A1 (en) 1999-04-29
AP2000001811A0 (en) 2000-06-30
JP4276379B2 (ja) 2009-06-10
CA2307175A1 (en) 1999-04-29
PT1090128E (pt) 2008-04-17
MY136336A (en) 2008-09-30
ATE390486T1 (de) 2008-04-15
JP2001520042A (ja) 2001-10-30
EP1090128B1 (en) 2008-03-26
AR035786A2 (es) 2004-07-14
EP1676919A1 (en) 2006-07-05
EA200000449A1 (ru) 2000-12-25
BR9814611A (pt) 2000-10-03
AR020048A1 (es) 2002-04-10
HUP0102257A2 (hu) 2001-09-28
NO20002025D0 (no) 2000-04-18
DK1090128T3 (da) 2008-06-23
PL194194B1 (pl) 2007-05-31
CA2307175C (en) 2009-04-14
NZ504114A (en) 2002-10-25
PL340284A1 (en) 2001-01-29
NO20002025L (no) 2000-06-19
ID26330A (id) 2000-12-14
IS5449A (is) 2000-04-14
IL135603A0 (en) 2001-05-20
SG105547A1 (en) 2004-08-27
AU749279C (en) 2004-09-16
HU225993B1 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
CN1246462C (zh) 修饰的维生素k依赖性多肽
CN1202128C (zh) 修饰蛋白的免疫原性
CN1192109C (zh) 锚定于细胞膜的抗凝血融合蛋白
CN1630721A (zh) 人凝血因子vii变体
CN1602354A (zh) 人凝血因子ⅶ多肽
CN1400910A (zh) 凝血因子VⅡ或VⅡa样分子
CN1326467A (zh) 表达以及分泌制管张素和endostatin的免疫融合物
CN86100868A (zh) 表达人类c蛋白的活性的载体和方法
CN1110323A (zh) 新多肽和编码它们的脱氧核糖核酸
CN1527726A (zh) 红细胞生成素共轭物
CN1768138A (zh) 在微生物中生产重组蛋白质的方法
CN1282372A (zh) 哺乳动物细胞因子样多肽－10
CN1839203A (zh) 因子VII或VIIa的GLA结构域变体
CN1104501C (zh) 修饰的人c3蛋白质
CN1258315A (zh) 哺乳动物细胞因子样因子7
CN1809370A (zh) B7－h3作为免疫调节剂的应用
CN1774448A (zh) 生长因子复合物及细胞迁移和生长的调节
CN1433466A (zh) Masp－3,一种固定补体的酶,及其应用
CN1229498C (zh) 重组的核糖核酸酶蛋白质
CN1226174A (zh) 应用蛋白酶抑制剂预防或降低骨的吸收
CN1863908A (zh) 凝固因子ⅶ多肽
CN1091139A (zh) 蛋白质酪氨酸磷酸酶的ptp-d亚家族
CN1161468C (zh) Mpl配体类似物
CN1445236A (zh) 促进毛发生长的寡肽
CN1934252A (zh) 凝血酶衍生物以及含有所述凝血酶衍生物的医药组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060322

Termination date: 20161020